Dapagliflozin effectively improves vascular endothelial functions in Diabetics complicated by CAD

Results

• The two groups had similar outcome indices upon admission (P > 0.05).
• After 20 weeks of medication, the two groups of patients showed similar blood pressure, hemoglobin A1c (HbA1c), and low-density lipoprotein (LDL-C) levels versus those before treatment (P > 0.05), and no significant differences were found in intergroup comparison neither (P > 0.05).
• When compared with the sole use of conventional hypoglycemic agents, Dapagliflozin plus conventional hypoglycemic agents resulted in a significantly higher reactive hyperemia index (RHI) value, fewer cases with abnormal vascular endothelial function, and fewer major cardiovascular events during treatment (P < 0.05).
• There was no significant difference in drug-related adverse events between the two groups (P > 0.05).  

Thus, the researchers concluded that Dapagliflozin improved the vascular endothelial functions of patients with diabetes mellitus complicated by coronary artery disease. It also had a high safety profile and favorable efficacy. 

For further reading: 10.1155/2022/4829750

Ma F, Zhang J, Wang H, Wu Y, Wu Y. Efficacy of Dapagliflozin in Patients with Diabetes Mellitus Complicated with Coronary Artery Disease and Its Impact on the Vascular Endothelial Function. Dis Markers. 2022;2022:4829750. Published 2022 Sep 9.